GSK PLC closed 20.84% below its 52-week high of £18.24, which the company achieved on May 16th.

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

Adding fluorine to drug molecules can be tricky, but is often worthwhile. Rachel Brazil talks to the chemists trying to tame ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...